Organovo Holdings, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
VivoSim Labs, Inc. reported a net loss of $1.3 million for the quarter ended June 30, 2026, with significant cash burn and substantial doubt about its going concern status, despite a recent capital raise.
VivoSim Labs, Inc. reports substantial doubt about its ability to continue as a going concern, despite a strategic pivot to 3D human tissue models for drug testing and the sale of its FXR program.
VivoSim Labs, Inc. reports a reduced net loss but faces substantial doubt about its ability to continue as a going concern, despite a strategic shift to 3D human tissue models and promising liver toxicology platform results.
Organovo Holdings reports Q3 2025 financial results, highlighting ongoing efforts in FXR314 development and 3D tissue modeling, while acknowledging substantial doubt about its ability to continue as a going concern.
Organovo Holdings, Inc., a clinical-stage biotechnology company, reported progress in its development of FXR314 for inflammatory bowel disease and its 3D tissue models, while also facing a Nasdaq minimum bid price deficiency notice.
Organovo Holdings reported its first quarter 2025 results, highlighting a focus on advancing its FXR314 program and developing 3D tissue models for drug discovery.
Organovo Holdings reports a net loss of $3.6 million for the third quarter of 2023, as it shifts focus to clinical drug development and 3D tissue models.